PMID- 31815114
OWN - NLM
STAT- MEDLINE
DCOM- 20200529
LR  - 20200529
IS  - 2291-2797 (Electronic)
IS  - 2291-2789 (Print)
IS  - 2291-2789 (Linking)
VI  - 2019
DP  - 2019
TI  - As Clinical Markers, Hand-Foot-Skin Reaction and Diarrhea Can Predict Better 
      Outcomes for Hepatocellular Carcinoma Patients Receiving Transarterial 
      Chemoembolization plus Sorafenib.
PG  - 2576349
LID - 10.1155/2019/2576349 [doi]
LID - 2576349
AB  - BACKGROUND: Combination therapy of transarterial chemoembolization plus sorafenib 
      (TACE-S) has been proven to be safe and effective for hepatocellular carcinoma 
      (HCC); however, this combination therapy is associated with a high incidence of 
      adverse events (AEs). Our study focused on the relationships between AEs and 
      treatment outcomes and aimed to discover AE-based clinical markers that can 
      predict the survival benefits of combination treatment. METHODS: From January 
      2010 to June 2014, a total of 235 HCC patients treated with TACE-S were 
      retrospectively enrolled. Major sorafenib-related AEs were prospectively 
      recorded, and their correlations with overall survival (OS) were analysed using 
      time-dependent covariate Cox regression analyses. RESULTS: The majority of the 
      patients (200, 85.1%) were male, and the median age was 51 years old. After two 
      years of follow-up, the median OS of the study population reached 12.4 months. In 
      all, 218 patients (92.8%) presented at least one AE, and 174 (74.0%) suffered AEs 
      >/=2 grade. Based on time-dependent multivariate analyses, the development of 
      hand-foot skin reaction (HFSR) >/=2 grade (HR = 0.43, 95% CI: 0.32-0.58, P < 0.001) 
      and diarrhoea >/=1 grade (HR = 0.72, 95% CI: 0.53-0.97, P=0.029) were identified as 
      independent predictors of prolonged OS. Moreover, patients who developed both 
      HFSR >/=2 grade and diarrhoea >/=1 grade achieved better outcomes than those patients 
      who developed either or neither of these AEs (HR = 1.51, 95% CI: 1.11-2.06, 
      P=0.009). CONCLUSIONS: The development of HFSR >/=2 grade or diarrhoea >/=1 grade 
      during TACE-S treatment indicated prolonged OS, and these AEs should be 
      considered important clinical markers for predicting patient prognoses.
CI  - Copyright (c) 2019 Lei Liu et al.
FAU - Liu, Lei
AU  - Liu L
AUID- ORCID: 0000-0003-4147-2760
AD  - Cell Engineering Research Center and Department of Cell Biology, State Key 
      Laboratory of Cancer Biology, Air Force Medical University, Xi'an 710032, China.
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Air Force 
      Medical University, Xi'an 710038, China.
FAU - Wang, Enxin
AU  - Wang E
AD  - Department of Liver Disease and Digestive Interventional Radiology, Xijing 
      Hospital of Digestive Diseases, Air Force Medical University, Xi'an 710032, 
      China.
FAU - Li, Lin
AU  - Li L
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Air Force 
      Medical University, Xi'an 710038, China.
FAU - Chen, Dongyu
AU  - Chen D
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Air Force 
      Medical University, Xi'an 710038, China.
FAU - Peng, Kun
AU  - Peng K
AD  - Department of Medical Imaging, 153th Central Hospital of the Chinese People's 
      Liberation Army, Zhengzhou 450100, China.
FAU - Wang, Mengmeng
AU  - Wang M
AD  - Department of Drug and Equipment, Aeromedicine Identification and Training Centre 
      of Air Force, 26 Huaqing Road, Lintong District, Xi'an 710069, China.
FAU - Han, Guohong
AU  - Han G
AUID- ORCID: 0000-0003-2320-1270
AD  - Department of Liver Disease and Digestive Interventional Radiology, Xijing 
      Hospital of Digestive Diseases, Air Force Medical University, Xi'an 710032, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20191114
PL  - Egypt
TA  - Can J Gastroenterol Hepatol
JT  - Canadian journal of gastroenterology & hepatology
JID - 101623613
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers)
RN  - 9ZOQ3TZI87 (Sorafenib)
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents/*therapeutic use
MH  - Biomarkers
MH  - Carcinoma, Hepatocellular/mortality/*therapy
MH  - Chemoembolization, Therapeutic/*adverse effects
MH  - Diarrhea/*etiology/mortality
MH  - Female
MH  - Humans
MH  - Liver Neoplasms/mortality/*therapy
MH  - Male
MH  - Middle Aged
MH  - Predictive Value of Tests
MH  - Retrospective Studies
MH  - Skin Diseases/*etiology/mortality
MH  - Sorafenib/*therapeutic use
MH  - Survival Rate
MH  - Treatment Outcome
PMC - PMC6877904
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2019/12/10 06:00
MHDA- 2020/05/30 06:00
PMCR- 2019/11/14
CRDT- 2019/12/10 06:00
PHST- 2019/05/09 00:00 [received]
PHST- 2019/07/13 00:00 [revised]
PHST- 2019/07/28 00:00 [accepted]
PHST- 2019/12/10 06:00 [entrez]
PHST- 2019/12/10 06:00 [pubmed]
PHST- 2020/05/30 06:00 [medline]
PHST- 2019/11/14 00:00 [pmc-release]
AID - 10.1155/2019/2576349 [doi]
PST - epublish
SO  - Can J Gastroenterol Hepatol. 2019 Nov 14;2019:2576349. doi: 10.1155/2019/2576349. 
      eCollection 2019.